Erasca initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado initiated coverage of Erasca with a Buy rating and $10 price target. The analyst views Erasca’s pipeline as being the “best-in-class comprehensive attack” on the MAPK pathways, potentially yielding access to a $20B potential market in multiple indications by 2034.